Thioctic Acid
PreclinicalSmall molecule
Thioctic Acid is one of 10 small molecule programs targeting Myopathy. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Myopathy
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Zocor
OOrganon and Co
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mesnex
BBaxter Healthcare Corporation
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Dantrium
AAultman Health Foundation
Phase 3
Salbutamol
GSKPreclinical
Coenzyme Q10
MMclean Hospital
Preclinical
Thioctic Acid
MMEDA Pharma GmbH & Co. KG
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetic Nephropathy1 trial
Alpha-lipoic Acid in Diabetic Nephropathy
Unknown status·—·Phase 3·NCT06253429·30 enrolled
Diabetic Neuropathy1 trial
Diabetic Polyneuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thioctic Acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMEDA Pharma GmbH & Co. KG